ライフサイエンスコーパス: subcutaneous fat

1 circulating, free base form of the drug into subcutaneous fat.

2 earch applications that consider measures of subcutaneous fat.

3 n the liver, intermuscular fat, or abdominal subcutaneous fat.

4 -specific recycling of circulating FFAs into subcutaneous fat.

5 gene in epididymal adipose tissue but not in subcutaneous fat.

6 alysis measurements of glycerol release from subcutaneous fat.

7 gher resistin mRNA levels in human abdominal subcutaneous fat.

8 lipolysis and lipogenesis in human abdominal subcutaneous fat.

9 factor-alpha (by 72%) and leptin (by 60%) in subcutaneous fat.

10 increased cardiometabolic risk compared with subcutaneous fat.

11 49653 in small arteries (n = 44) from human subcutaneous fat.

12 liver, lung, myocardium, skeletal muscle, or subcutaneous fat.

13 ross-sectional area, muscle attenuation, and subcutaneous fat.

14 tion favors more truncal and less peripheral subcutaneous fat.

15 and mouse epididymal fat compared with their subcutaneous fat.

16 h and PTRF mRNA levels was observed in human subcutaneous fat.

17 l bone density, trabecular bone content, and subcutaneous fat.

18 se in visceral (intra-abdominal) compared to subcutaneous fat.

19 he connection between the nervous system and subcutaneous fat.

20 ody mass index, total body fat, or abdominal subcutaneous fat.

21 ge enzymes/proteins in omental and abdominal subcutaneous fat.

22 ations among discrimination and visceral and subcutaneous fat.

23 nsidered important and valid measurements of subcutaneous fat.

24 icantly increased their total, visceral, and subcutaneous fat.

25 , resulting in a higher ratio of visceral to subcutaneous fat (0.15 [0.02] vs 0.07 [0.01], p=0.002).

26 3 cm2 vs +3 cm2, respectively; P = .001) and subcutaneous fat (-13 cm2 vs +2 cm2, P = .003).

27 4-387), colostomy (5.07; 2.12-13.0), thicker subcutaneous fat (2.02; 1.33-3.21), and black race (0.35

28 ed weight (-2.9%) and BMI (-2.9%) in men and subcutaneous fat (-3.6% at L2-L3 and -4.7% at L4-L5), we

29 3] vs 1.99 [0.19]%, p=0.03), lower abdominal subcutaneous fat (460 [47] vs 626 [39] cm2, p=0.04), and

30 Invasion beyond subcutaneous fat also predicted overall death (HR, 2.1 [

31 13.8%) abdominal fat: 1.5 +/- 0.2 kg (13.6%) subcutaneous fat and 0.9 +/- 0.1 kg (16.1%) visceral fat

32 with histologic examination of the skin and subcutaneous fat and evaluation of the skin during reduc

33 reated with antiretroviral agents often lose subcutaneous fat and have metabolic abnormalities, inclu

34 dwarfism, lordokyphosis, cataracts, loss of subcutaneous fat and impaired wound healing.

35 Abdominal and subcutaneous fat and increased liver weight account for

36 atrophy syndrome is characterized by loss of subcutaneous fat and is associated with increased restin

37 gest that SPARC expression is predominant in subcutaneous fat and its expression and secretion in adi

38 ft-tissue mass with infiltration of adjacent subcutaneous fat and minimal or no extension into the bo

39 d by a layered closure of the ischioanal and subcutaneous fat and skin similar to the control interve

40 re racial differences in the distribution of subcutaneous fat and the length of the limbs relative to

41 were compared with total body fat, abdominal subcutaneous fat, and abdominal visceral fat in univaria

42 occur in higher numbers in visceral than in subcutaneous fat, and in female versus male mice.

43 the high fat-fed state, enhanced browning of subcutaneous fat, and increased adipose expression of GL

44 ction on DNL, liver fat, visceral fat (VAT), subcutaneous fat, and insulin kinetics in obese Latino a

45 tional QTL influencing heat loss, percentage subcutaneous fat, and percentage heart was found for chr

46 EBCT-defined CAC scores, visceral and subcutaneous fat, and statin use were assessed in 2001 t

47 metabolic phenotype and the browning of the subcutaneous fat are impaired by the suppression of type

48 (109.5 cm2 vs. 152.9 cm2) but a higher mean subcutaneous fat area (287.8 cm2 vs. 214.6 cm2).

49 leptin levels were strongly associated with subcutaneous fat area (r = 0.760) but not with intra-abd

50 level of the umbilicus, total, visceral, and subcutaneous fat area (TFA [total fat area], VFA [viscer

51 The subcutaneous fat area at each site was calculated by sub

52 Subcutaneous fat area can be estimated well by linear me

53 ciated and predicted more of the variance in subcutaneous fat area than in intra-abdominal fat area.

54 Total subcutaneous fat area was calculated as the sum of these

55 Total subcutaneous fat area was defined as total fat area minu

56 ypertension, even after adjustment for total subcutaneous fat area, abdominal subcutaneous fat area,

57 hypertension even after adjustment for total subcutaneous fat area, abdominal subcutaneous fat area,

58 , when LIS and LIR subjects were matched for subcutaneous fat area, age, and gender, they had similar

59 ression model after adjustment for abdominal subcutaneous fat area, age, sex, 2-h plasma glucose leve

60 For subcutaneous fat area, all anthropometric indices were l

61 t for total subcutaneous fat area, abdominal subcutaneous fat area, body mass index, or waist circumf

62 For each 1-cm(2) decrease in abdominal subcutaneous fat area, leptin decreased by 0.044 ng/mL w

63 t for total subcutaneous fat area, abdominal subcutaneous fat area, or waist circumference; however,

64 10-11 years even after adjustment for total subcutaneous fat area, total fat area, BMI, or waist cir

65 fat area], VFA [visceral fat area], and SFA [subcutaneous fat area], respectively).

66 c studies and quantification of visceral and subcutaneous fat areas (VFA and SFA) using abdominal com

67 white ethnicity had intra-abdominal fat and subcutaneous fat areas measured as part of the Atheroscl

68 ometric indices with intra-abdominal fat and subcutaneous fat areas measured by magnetic resonance im

69 Intra-abdominal fat and subcutaneous fat areas were quantified by computed tomog

70 und in visceral adipose tissue and abdominal subcutaneous fat areas.

71 amined nonadipocyte stromal cells from human subcutaneous fat as a novel source of therapeutic cells.

72 Abdominal visceral fat (AVF), abdominal subcutaneous fat (ASF), and abdominal total fat (ATF) we

73 ance (beta=0.08, P<0.05), whereas lower body subcutaneous fat associated with higher cardiac output (

74 2%) and at L4-L5 (men -22.4%, women -17.8%), subcutaneous fat at L2-L3 (men -15.7%, women -11.4%) and

75 Body fat was determined by DXA, and subcutaneous fat at triceps, biceps, subscapular, suprai

76 rteriovenous difference across the abdominal subcutaneous fat bed in humans.

77 us dose of [1-(14)C]oleate followed by timed subcutaneous fat biopsies (abdominal and femoral) and th

78 ]palmitate followed by omental and abdominal subcutaneous fat biopsies to measure direct FFA storage.

79 Subcutaneous fat biopsies were obtained from the upper t

80 nd adipose triglyceride lipase expression in subcutaneous fat biopsies.

81 acers were intravenously infused followed by subcutaneous fat biopsies.

82 Adipocytes collected from subcutaneous fat biopsy samples after normal and restric

83 enes in a subset of subjects who underwent a subcutaneous fat biopsy.

84 Abdominal subcutaneous fat, but not visceral fat, area was higher

85 pose stromal cells from omental fat, but not subcutaneous fat, can generate active cortisol from inac

86 the significantly reduced H-Ras occurred in subcutaneous fat cells, while the reduced PI3K and PCNA

87 gene, PLIN2, expressed only by sebocytes and subcutaneous fat cells.

88 n SR: history of fascial dehiscence, thicker subcutaneous fat, colostomy, and white race.

89 inal fat mass, and increased extra-abdominal subcutaneous fat, compared with wild-type mice.

90 absorptiometry), and abdominal visceral and subcutaneous fat (computed tomography) were measured in

91 revented weight gain, decreased visceral and subcutaneous fat content (P < 0.03 and 0.01, respectivel

92 Subcutaneous fat correlated significantly with mean lept

93 to cortisone) and was higher in omental than subcutaneous fat (cortisone to cortisol, median 57.6 pmo

94 Subcutaneous fat declined (-17.2%; P < 0.001), whereas t

95 ross tertiles, BMI and percentage of fat and subcutaneous fat decreased, while hepatic fat increased.

96 ed rats did have increased plasma leptin and subcutaneous fat deposition and markedly abnormal glucos

97 correlates with insulin resistance, whereas subcutaneous fat deposition correlates with circulating

98 Excessive non-subcutaneous fat deposition may impair the functions of

99 The overall burden of non-subcutaneous fat deposition, but not abdominal subcutane

100 BMI and WHR depends on the assumed model of subcutaneous fat deposition.

101 percentage of total fat tissue but had more subcutaneous-fat deposition than did the uninfected cont

102 ter [P = 0.38] and pterygoid [P = 0.70]) and subcutaneous fat deposits (neck [P = 0.44] and submental

103 hether an imbalance between the visceral and subcutaneous fat depots and a corresponding dysregulatio

104 ptake into visceral and upper and lower body subcutaneous fat depots in 21 premenopausal women.

105 ed to the phenotype of high visceral and low subcutaneous fat depots in obese adolescents.

106 Intraabdominal and subcutaneous fat depots were two- to threefold greater i

107 We examined the role of visceral and subcutaneous fat depots, independent of BMI, on the dysl

108 Changes in body weight, visceral and subcutaneous fat depots, oral glucose tolerance, insulin

109 us fat index with the standard scores of non-subcutaneous fat depots.

110 Gonadal fat develops postnatally, whereas subcutaneous fat develops between embryonic days 14 and

111 m-operated animals, whereas transplants with subcutaneous fat did not affect atherosclerosis despite

112 Measures of intraabdominal and subcutaneous fat did not predict fasting hyperinsulinemi

113 APCs derived from subcutaneous fat differentiate well in the presence of c

114 iety response and have altered abdominal and subcutaneous fat distribution, with Rai1(+/-) female mic

115 se in rodents and humans, while expansion of subcutaneous fat does not carry the same risks.

116 ed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU.m(-2).

117 Increased visceral fat, rather than subcutaneous fat, during the onset of obesity is associa

118 lin sensitive, which correlated with massive subcutaneous fat expansion.

119 rkedly inhibited beige adipocyte function in subcutaneous fat following cold exposure or beta3-agonis

120 ting lungs, anisotropic skeletal muscle, and subcutaneous fat) forward models were compared with meas

121 of the defatted dry matter and marbling and subcutaneous fat fractions, were assessed on 86 ham samp

122 , from 43.1+/-4.5 kg/m2 to 32.3+/-4.0 kg/m2, subcutaneous fat from 649+/-162 cm2 to 442+/-127 cm2, VA

123 fat gain (rho=-0.42, p=0.004), but not with subcutaneous fat gain (rho=-0.22, p=0.15).

124 is was altered; Rosi-induced body weight and subcutaneous fat gain and liver lipid accumulation were

125 trate that resident innate lymphoid cells in subcutaneous fat generate and activate beige adipocytes,

126 of visceral fat and relatively low abdominal subcutaneous fat have a phenotype reminiscent of partial

127 composition and energy stores in the form of subcutaneous fat have long-term effects on offspring BP

128 ratio of abdominal visceral fat to abdominal subcutaneous fat improved significantly more in the GHRH

129 direct FFA storage in abdominal and femoral subcutaneous fat in 10 and 11 adults, respectively, duri

130 fat distribution, ie, significant losses of subcutaneous fat in association with metabolic abnormali

131 of MRI to quantify fat content in flesh and subcutaneous fat in fish cutlets was investigated.

132 Discrimination was not associated with subcutaneous fat in minimally (P = 0.95) or fully adjust

133 egulated in human visceral fat compared with subcutaneous fat in obese individuals.

134 ting free fatty acids (FFAs) in visceral and subcutaneous fat in postabsorptive women.

135 eater gestational weight gain and accrual of subcutaneous fat in the mother but lower fetal growth co

136 rates were greater in omental than abdominal subcutaneous fat in women (1.2 +/- 0.8 vs. 0.7 +/- 0.4 m

137 asis after RYGB is associated with decreased subcutaneous fat, increased postprandial PYY, GLP-1, and

138 and CD8 T-cell infiltrates in the dermis and subcutaneous fat, increased serum immunoglobulin G2a lev

139 associated with a 1 SD increment in the non-subcutaneous fat index [odds ratio (OR): 1.41; 95% CI: 1

140 The relation between non-subcutaneous fat index and calcified coronary plaque rem

141 each depot separately, we also created a non-subcutaneous fat index with the standard scores of non-s

142 Transplantation of subcutaneous fat into mice with diet-induced obesity sho

143 for patients who had histologic evidence of subcutaneous fat involvement in comparison with patients

144 ss than 10g lipid per 100g after trimming of subcutaneous fat, irrespective of age.

145 We also found that SirT1 expression in human subcutaneous fat is inversely related to adipose tissue

146 shows that the short TCF7L2 mRNA variant in subcutaneous fat is regulated by weight loss and is asso

147 ascular endothelial cells (EC) from lung and subcutaneous fat is slow, like HDMEC, whereas internaliz

148 fraction occurs at the interface between the subcutaneous fat layer and the glandular parenchyma and

149 Rates of whole-body and subcutaneous fat lipolysis were assessed by measuring th

150 s that include profound lymphopenia, loss of subcutaneous fat, lordokyphosis, and severe metabolic de

151 te the relation between leptin secretion and subcutaneous fat loss in HIV-infected patients.

152 gnificant reduction in leptin secretion with subcutaneous fat loss in this population.

153 ial Dunnigan lipodystrophy, characterized by subcutaneous fat loss, is frequently caused by an R482W

154 ed waist circumference (11-13 cm), abdominal subcutaneous fat mass (1650-1850 cm(3)), visceral fat ma

155 ing for percent total body fat and abdominal subcutaneous fat mass (partial correlation r = -0.73, P

156 android/gynoid ratio, and preperitoneal and subcutaneous fat mass by physical examinations, dual-ene

157 Subcutaneous fat mass was not associated with any respir

158 ing to measure accurately intraabdominal and subcutaneous fat masses in 14 obese [body mass index (BM

159 to the higher total fat and particularly the subcutaneous fat masses.

160 versus 20.8+/-2.4 kg, P>0.05) and abdominal subcutaneous fat-matched (230.6+/-24.9 versus 261.4+/-34

161 I) for assessment of whole body visceral and subcutaneous fat, maximal aerobic capacity test and musc

162 bcutaneous fat deposition, but not abdominal subcutaneous fat, may be a correlate of coronary atheros

163 six sites (240 soft-tissue, colonic gas, and subcutaneous fat measurements).

164 increased adipogenesis and/or lipogenesis in subcutaneous fat, mediated by the LPIN1 gene, may preven

165 During cold-induced 'browning' of subcutaneous fat, most 'beige' adipocytes stem from de n

166 13, and 13a, decreased after weight loss in subcutaneous fat (n = 46) and liver (n = 11) and was mor

167 rse events were reported in the xenon group: subcutaneous fat necrosis and transient desaturation dur

168 gth in leukocytes, skeletal muscle, skin and subcutaneous fat of 87 adults (aged 19-77 years).

169 Cs) and whole-fat tissues from the abdominal subcutaneous fat of obese and nonobese subjects, we show

170 6) and liver (n = 11) and was more common in subcutaneous fat of subjects with type 2 diabetes than i

171 mals (P = 0.748) that was not due to reduced subcutaneous fat or LBM, but rather preferential loss of

172 ained after further adjustment for abdominal subcutaneous fat (OR: 1.40; 95% CI: 1.00, 1.94).

173 aging including sarcopenia, cataracts, less subcutaneous fat, organ shrinkage, and others.

174 her amount of total body fat (p < 0.001) and subcutaneous fat (p < 0.001) than those without NAFLD.

175 verage, 28% greater total fat and 30% higher subcutaneous fat (P <.001 for both), but 10% less parasp

176 In stepwise regression modeling, subcutaneous fat (P <0.0001), but not visceral fat, was

177 e uptake of meal FAs increased in upper-body subcutaneous fat (P = 0.028) in weight-reduced UOb women

178 cm or greater (P<.001), invasion beyond the subcutaneous fat (P<.003), multiple nerve involvement (P

179 ntly blunted angiogenic growth compared with subcutaneous fat (P<0.001) that was associated with mark

180 significantly elevated in the epididymal and subcutaneous fat pads from ob/ob mice compared with thei

181 ver, spleen, kidneys, bone marrow, skin, and subcutaneous fat pads from these mice showed no abnormal

182 ncreasing adiposity in the visceral, but not subcutaneous, fat pads of ob/ob mice.

183 Increased visceral rather than subcutaneous fat predicts endothelial dysfunction.

184 otal fat mass (r=0.323, P<0.05) or abdominal subcutaneous fat (r=0.27, P=0.05).

185 ge, 34.4%-54.9%) and significantly lower for subcutaneous fat (range, 10.3%-12.6%), compared with tha

186 Visceral and the visceral-to-subcutaneous fat ratio increased and insulin sensitivity

187 profile, including an increased visceral to subcutaneous fat ratio, insulin resistance, dyslipidemia

188 onoclonal gammopathy, a unique patterning of subcutaneous fat reticulation and hypodense bone marrow

189 factors for metastasis were: invasion beyond subcutaneous fat (RR, 11.21; 95% CI, 3.59-34.97), Breslo

190 , 4.55; 95% CI, 1.41-14.69), invasion beyond subcutaneous fat (RR, 4.49; 95% CI, 2.05-9.82), and peri

191 , 9.64; 95% CI, 1.30-71.52), invasion beyond subcutaneous fat (RR, 7.61; 95% CI, 4.17-13.88), Breslow

192 index (Si) and intra-abdominal fat (IAF) and subcutaneous fat (SCF) areas.

193 , as in control subjects, amounts of truncal subcutaneous fat showed a stronger correlation with gluc

194 Abdominal subcutaneous fat showed weaker associations with concent

195 rmula had greater accretion of visceral than subcutaneous fat, showed increased signs of macrophage i

196 orrelated positively with body-mass index in subcutaneous fat (Spearman correlation=0.51, p=0.006).

197 hydrate intake may have a stronger effect on subcutaneous fat storage than does dietary fat intake.

198 lation; (ii) skinfold thickness, to estimate subcutaneous fat stores necessary to fuel growth and imm

199 ra (T1, 586 msec +/- 73; T2, 49 msec +/- 4), subcutaneous fat (T1, 382 msec +/- 13; T2, 68 msec +/- 4

200 d to higher triglycerides and more total and subcutaneous fat than darunavir/ritonavir.

201 ge of meal FAs in both upper- and lower-body subcutaneous fat than did the LOb and UOb women (P = 0.0

202 les having more leptin and greater levels of subcutaneous fat than males.

203 al fibrosis with greater preservation of the subcutaneous fat than wild-type mice.

204 In the dermis and subcutaneous fat, the EVE treated groups showed signific

205 For subcutaneous fat, the results were compared with vision

206 The abdominal fat area (AFA) and subcutaneous fat thickness (SFT) were measured using T1-

207 Exponential dose increases for increased subcutaneous fat thicknesses can be reduced substantiall

208 y was to quantify the anatomy of the muscle, subcutaneous fat, tibia, fibula and arteries in the lowe

209 no acute effect on WISP1 gene expression in subcutaneous fat tissue in overweight subjects who had u

210 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal, but not of leptin-rec

211 WISP1 expression in visceral and subcutaneous fat tissue was associated with markers of i

212 oth-root slices, which were filled with only subcutaneous fat tissue.

213 ly low expression in the gonads, gizzard and subcutaneous fat tissues of chickens.

214 We isolated MSCs from cardiac and subcutaneous fat tissues of mice with LVD 28 days after

215 Abdominal subcutaneous fat took up FFAs more avidly than femoral f

216 nitiates adipogenesis after 4 weeks, whereas subcutaneous fat undergoes hypertrophy for a period of u

217 h versus low ratio of visceral to visceral + subcutaneous fat (VAT/[VAT+SAT]).

218 Subcutaneous fat, visceral fat, paraspinous musculature,

219 vs. 52,321.87 +/- 5125.05 mm(3), p=0.01) and subcutaneous fat volume (10,599.89 +/- 3683.57 vs. -5224

220 Arm muscle and subcutaneous fat volumes were measured before and after

221 Subcutaneous fat was also significantly related to lepti

222 Subcutaneous fat was assessed on the basis of the averag

223 In contrast, lower body subcutaneous fat was associated with eccentric remodelin

224 In contrast, lower body subcutaneous fat was associated with higher LV end-diast

225 was accurately detected, acceptable if only subcutaneous fat was excluded, or unacceptable if any br

226 Visceral and subcutaneous fat was measured using T(2) (*)-IDEAL.

227 -induced visceral adipose formation, whereas subcutaneous fat was reduced similarly in both groups.

228 , visceral adipose tissue, but not abdominal subcutaneous fat, was significantly associated with conc

229 Visceral and subcutaneous fat were assessed via computed tomography s

230 Body weight and subcutaneous fat were decreased after RYGB, compared wit

231 Liver fat, VAT, and subcutaneous fat were determined by magnetic resonance s

232 ion, tumor diameter >/=2 cm, invasion beyond subcutaneous fat) were incorporated in the alternative s